Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance

• Published in: Cancer cytopathology Vol. 129; no. 12; p. 947
• Main Authors: Onken, Allison M, VanderLaan, Paul A, Hennessey, James V, Hartzband, Pamela, Nishino, Michiya
• Format: Journal Article
• Language: English
• Published: United States 01.12.2021
• Subjects: Adenocarcinoma, Follicular - pathology; Biopsy, Fine-Needle; Carcinoma, Papillary - pathology; Humans; Retrospective Studies; Thyroid Neoplasms - diagnosis; Thyroid Neoplasms - genetics; Thyroid Neoplasms - surgery; Thyroid Nodule - diagnosis; Thyroid Nodule - genetics; Thyroid Nodule - surgery; noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); thyroid; molecular testing; cancer; fine-needle aspiration; Afirma; indeterminate cytology
• ISSN: 1934-6638
• DOI: 10.1002/cncy.22489

Thyroid nodules classified as atypia of uncertain significance (AUS) on fine-needle aspiration cytology are heterogeneous. Prior studies reported a higher risk of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)/cancer among AUS nodules that had cytologic (AUS-C) versus architectural (AUS-A) atypia; however, such studies were generally confined to resected cohorts, introducing bias into risk calculations. The authors hypothesized that combined histologic and molecular end points would permit clinically meaningful calculations of NIFTP/malignancy risk among AUS nodules. The study consisted of 279 thyroid nodules classified as AUS on initial fine-needle aspiration and tested by the Afirma Gene Expression Classifier (GEC) between June 2013 and October 2017. Results of GEC testing and histopathologic diagnoses were stratified by AUS classifiers. The AUS-A category was further subclassified as 1) hypocellular microfollicular or 2) cellular with mixed but predominantly microfollicular architecture. NIFTP/cancer risk was calculated for each subgroup, with the inclusion of unresected nodules that had benign GEC results as low-risk end points comparable to histologically benign nodules. When only histologic end points were considered, there was no difference in NIFTP/cancer risk (25% vs 23%; P = .82). By using molecular and histologic end points, AUS cases with cytologic atypia trended toward higher NIFTP/cancer risk than AUS-A cases (14% vs 6%; P = .06). Furthermore, AUS-A cases showed a trend toward lower NIFTP/cancer risk for hypocellular microfollicular aspirates (3%) compared with cellular samples that had mixed/predominantly microfollicular architecture (13%; P = .18). The inclusion of unresected benign GEC nodules in risk-of-malignancy calculations provides more accurate results, which may be helpful for informing patient management as well as quality improvement in the cytopathology laboratory.